MP53-17 PATIENT-REPORTED OUTCOMES AFTER PROSTATE ONLY VS PROSTATE AND PELVIC LYMPH NODE RADIATION THERAPY

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Radiation Therapy (MP53)1 Apr 2020MP53-17 PATIENT-REPORTED OUTCOMES AFTER PROSTATE ONLY VS PROSTATE AND PELVIC LYMPH NODE RADIATION THERAPY Matthew Parry*, Julie Nossiter, Thomas Cowling, Arunan Sujenthiran, Brendan Berry, Paul Cathcart, Noel Clarke, Heather Payne, Jan van der Meulen, and Ajay Aggarwal Matthew Parry*Matthew Parry* More articles by this author , Julie NossiterJulie Nossiter More articles by this author , Thomas CowlingThomas Cowling More articles by this author , Arunan SujenthiranArunan Sujenthiran More articles by this author , Brendan BerryBrendan Berry More articles by this author , Paul CathcartPaul Cathcart More articles by this author , Noel ClarkeNoel Clarke More articles by this author , Heather PayneHeather Payne More articles by this author , Jan van der MeulenJan van der Meulen More articles by this author , and Ajay AggarwalAjay Aggarwal More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000915.017AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Little is known about the toxicity of pelvic lymph node (PLN) irradiation following intensity-modulated radiation therapy (IMRT) for the treatment of men with high-risk prostate cancer. We aimed to compare patient-reported outcomes of IMRT to the prostate and the pelvic lymph nodes (PPLN-IMRT) compared to prostate only IMRT (PO-IMRT). METHODS: Patients diagnosed with high-risk or locally advanced prostate cancer in the English National Health Service, between April 2014 and September 2016, and treated with IMRT were identified from the National Prostate Cancer Audit. Men were mailed a questionnaire 18 months after diagnosis. Patient-reported sexual, urinary, bowel and hormonal function domains using the EPIC-26, and generic health-related quality of life (HRQoL) using EQ-5D-5L, were collected from patient surveys. Comparator groups (PPLN-IMRT versus PO-IMRT) were compared using linear regression, adjusting for baseline patient, tumour and treatment characteristics. RESULTS: Of the 5468 men (78%) who responded to the patient survey, 4196 (77%) received PO-IMRT and 1272 (23%) received PPLN-IMRT. Adjusted mean scores for urinary, bowel, and hormonal EPIC-26 domains, and HRQoL were similar irrespective of the treatment region. Patients receiving PPLN-IMRT reported worse sexual function than those receiving PO-IMRT (-2.26 adjusted mean difference on a 0-100 scale; 95% CI: -3.66 to -0.86, P =0.002) but this was not a clinically meaningful difference. CONCLUSIONS: PPLN-IMRT is not associated with clinically important differences in patient-reported toxicity for men with high-risk or locally advanced prostate cancer. Results from ongoing trials will provide further insight into the anti-cancer effectiveness of PLN irradiation. Source of Funding: M.G.P. was supported by a Doctoral Research Fellowship from the NHS National Institute for Health Research (DRF-2018-11-ST2-036). T.E.C. was supported by the Medical Research Council (MR/S020470/1). B.B. was partly supported by the NHS National Institute for Health Research through an Academic Clinical Fellowship. H.P. was supported by the University College London Hospitals/University College London Comprehensive Biomedical Research Centre. J.v.d.M. was partly supported by the NIHR Collaboration for Leadership in Applied Health Research and Care North Thames at Bart’s Health NHS Trust. The views expressed in this article are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e789-e789 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Matthew Parry* More articles by this author Julie Nossiter More articles by this author Thomas Cowling More articles by this author Arunan Sujenthiran More articles by this author Brendan Berry More articles by this author Paul Cathcart More articles by this author Noel Clarke More articles by this author Heather Payne More articles by this author Jan van der Meulen More articles by this author Ajay Aggarwal More articles by this author Expand All Advertisement PDF downloadLoading ...